Abstract:PD-(L)1 inhibitors have provided new treatment approaches for patients with NSCLC; however, resistance to PD-(L)1 inhibitors or low PD-L1 expression may limit clinical benefit. Tislelizumab, a monoclonal antibody with high affinity and specificity for PD-1, was recently approved in China for the treatment of previously treated classical Hodgkin lymphoma. Tislelizumab was engineered to minimize binding to FcɣR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti- PD-1 therapy. Preliminary reports from this study (NCT04068519) showed that tislelizumab monotherapy was generally well tolerated and demonstrated antitumor activity in Chinese patients with advanced solid tumors. We now present data from patients with NSCLC. This multi-arm, open-label, nonrandomized phase 1/2 study evaluated safety/tolerability, antitumor activity, and survival in patients with histologically/cytologically confirmed advanced solid tumors treated with tislelizumab. Eligible patients progressed on, or were intolerant to, their last standard antitumor treatment and were anti-PD-(L)1 therapy treatment-naïve. Patients received intravenous tislelizumab 200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity. Patients were considered PD-L1-positive if ≥10% of their tumor cells had PD-L1 membrane staining at any intensity using the VENTANA PD-L1 (SP263) assay. Antitumor response was assessed by RECIST v1.1, overall survival (OS) was estimated by Kaplan-Meier analysis, and safety/tolerability was examined by monitoring adverse events (AEs). As of 01 December 2018, 56 patients with NSCLC (nonsquamous, n=31 [55%]; squamous, n=25 [45%]) were enrolled. Forty patients (71%) were male, 53 (95%) had metastatic disease, and 23 (41%) had never smoked; one patient each had an EGFR mutation or ALK rearrangement. Patients were heavily pretreated, with 16 patients (29%) receiving ≥3 lines of prior systemic therapy. The most common treatment-related AEs (TRAEs) were increased AST (n=14; 25%), increased ALT (n=13; 23%), and rash (n=8; 14%). Increased AST (n=3; 5%) and increased ALT (n=2; 4%) were the only grade ≥3 TRAEs occurring in ≥2 patients. Immune-related AEs (irAE) were reported in 12 patients (21%) and were generally of low severity, including 1 patient with grade 2 pneumonitis; 4 patients (7%) experienced a grade ≥3 irAE. The objective response rate (ORR) was 18% (95% CI: 8.9, 30.4), with an ORR of 17% (95% CI: 4.7, 37.4) and 19% (95% CI: 7.5, 37.5) in patients who were PD-L1-positive (n=24) and PD-L1-negative (n=31), respectively. With a median follow-up of 14.6 months (95% CI: 12.0, 15.6), median OS was not reached in patients with NSCLC. Updated data with a follow-up of ≥2 years will be presented, including OS. Tislelizumab was generally well tolerated and demonstrated antitumor activity in NSCLC patients regardless of PD-L1 expression status. Tislelizumab is being evaluated as a single agent or with chemotherapy in phase 3 studies in NSCLC patients (NCT03358875, NCT03594747, and NCT03663205).

OA07.09 Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo Vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

P1.04-02 Efficacy and Safety of Sintilimab with Anlotinib As First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

LBA57 MHC-II Antigen Presentation Pathway As a Predictive Biomarker for Sintilimab Plus Chemotherapy in First-Line Treatment of Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsq-Nsclc)

ID:1329 ORIENT-11: Sintilimab + Pemetrexed + Platinum As First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC

86P Efficacy and Safety of IBI110 (Anti-Lag-3 Mab) in Combination with Sintilimab (Anti-Pd-1 Mab) in Advanced Squamous Non-Small Cell Lung Cancer (sqnsclc): Updated Results of the Phase Ib Study

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

First-line Sintilimab Combined with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer: A Phase II Study and Post-Hoc Biomarker Analysis.

Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

OA03.04 Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study

Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC).

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)